Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

Audrey L. Smith; Dhananjaya Pal; Rolando Martinez-Rico; Alexandria P. Eiken; Donald L Durden; Tatiana G. Kutateladze; Dalia El-Gamal

doi:10.1080/10428194.2023.2256914

Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

Audrey L. Smith, Dhananjaya Pal, Rolando Martinez-Rico, Alexandria P. Eiken, Donald L Durden, Tatiana G. Kutateladze, Dalia El-Gamal

Eppley Institute for Cancer Research

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.1080/10428194.2023.2256914
State	Accepted/In press - 2023

Keywords

chronic lymphocytic leukemia
ibrutinib-resistance
Mantle cell lymphoma
novel BTK/PI3K/BRD4 inhibitor
targeted multi-axis treatment

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2023.2256914

Cite this

@article{c273c0e3729341498112668e86e48747,

title = "Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies",

keywords = "chronic lymphocytic leukemia, ibrutinib-resistance, Mantle cell lymphoma, novel BTK/PI3K/BRD4 inhibitor, targeted multi-axis treatment",

author = "Smith, {Audrey L.} and Dhananjaya Pal and Rolando Martinez-Rico and Eiken, {Alexandria P.} and Durden, {Donald L} and Kutateladze, {Tatiana G.} and Dalia El-Gamal",

note = "Funding Information: We thank SignalRx Pharmaceutical, Inc. for providing SRX3305 and SRX3333 and The Ohio State University Leukemia Tissue Bank staff for primary patient sample procurement services that was supported by the National Cancer Institute grant P30 CA016058. We also thank the Department of Pharmacology and Experimental Neuroscience Elutriation Core at the University of Nebraska Medical Center for the isolation of healthy donor PBLs used in this study. We acknowledge Jinxu Liu for initial inhibitor testing in malignant B-cells lines. ",

year = "2023",

doi = "10.1080/10428194.2023.2256914",

language = "English (US)",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

AU - Smith, Audrey L.

AU - Pal, Dhananjaya

AU - Martinez-Rico, Rolando

AU - Eiken, Alexandria P.

AU - Durden, Donald L

AU - Kutateladze, Tatiana G.

AU - El-Gamal, Dalia

N1 - Funding Information: We thank SignalRx Pharmaceutical, Inc. for providing SRX3305 and SRX3333 and The Ohio State University Leukemia Tissue Bank staff for primary patient sample procurement services that was supported by the National Cancer Institute grant P30 CA016058. We also thank the Department of Pharmacology and Experimental Neuroscience Elutriation Core at the University of Nebraska Medical Center for the isolation of healthy donor PBLs used in this study. We acknowledge Jinxu Liu for initial inhibitor testing in malignant B-cells lines.

PY - 2023

Y1 - 2023

KW - chronic lymphocytic leukemia

KW - ibrutinib-resistance

KW - Mantle cell lymphoma

KW - novel BTK/PI3K/BRD4 inhibitor

KW - targeted multi-axis treatment

UR - http://www.scopus.com/inward/record.url?scp=85170832303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170832303&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2256914

DO - 10.1080/10428194.2023.2256914

M3 - Letter

C2 - 37706519

AN - SCOPUS:85170832303

SN - 1042-8194

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

ER -

Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this